AstraZeneca battles to retain its talismanic leader
Pascal Soriot has been lauded for his role in the vaccine rollout, but angry shareholders may yet drive him out
Executives at AstraZeneca knew it would be a close call.
By the time the annual general meeting began, three of the UK’s most influential investor advisory groups had urged votes against the pay proposals and a shareholder revolt appeared all but inevitable.
As it turned out, AstraZeneca was dealt a bloody blow. Almost 40pc of its investors - including leading names Aviva Investors and Standard Life Aberdeen - voted against the proposal to hike the maximum share awards that Soriot could receive as well as his maximum annual bonus.
Covid-19: quién es quién en la carrera farmacéutica de la vacuna expansion.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from expansion.com Daily Mail and Mail on Sunday newspapers.